CORT - コ―セプト・セラピュ―ティクス （Corcept Therapeutics Incorporated）

Corcept Therapeutics Incorporated (NASDAQ:NASDAQ:CORT) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ETCompany ParticipantsAtabak Mokari - Chief Financial OfficerCharlie Robb - Chief…

Corcept Therapeutics press release (CORT): Q1 GAAP EPS of $0.14 misses by $0.05.Revenue of $105.7M (+12.8% Y/Y) beats by $0.79M.Cash and investments of $465.1 million as of March…

https://www.investing.com/news/pro/piper-sandler-starts-corcept-therapeutics-at-overweight-432SI-3048277

https://www.investing.com/news/assorted/corcept-therapeutics-initiates-catalyst-trial-432SI-3043015

MENLO PARK, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that it has initiated CATALYST, a 1,000-patient, Phase 4 trial examining the prevalence of hypercortisolism in patients with difficult to control type 2 diabetes. Those patients with hypercortisolism will be offered entry into a randomized, double-blind, placebo-controlled study of Korlym ® .

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q3 2022 Earnings Call dated Nov. 03, 2022.

Corcept Therapeutics Incorporated (NASDAQ:NASDAQ:CORT) Q3 2022 Earnings Conference Call November 03, 2022 05:00 PM ET Company Participants Joseph Belanoff - CEO and President Atabak Mokari…

MENLO PARK, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended September 30, 2022.

Corcept Therapeutics (NASDAQ: CORT ) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here''s what investors need to know before the announcement. Analysts estimate that Corcept Therapeutics will report an earnings per share (EPS) of $0.22. Corcept Therapeutics bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com

MENLO PARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2022. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Corcept Therapeutics (CORT) has commenced a phase 3 study of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.

Biotech stocks like Corcept Therapeutics are worth considering for your portfolio as shares near a proper buy point amid a powerful rally.

NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Carvana Co. (NYSE: CVNA), Enochian Biosciences, Inc. (NASDAQ: ENOB), Novartis AG (NYSE: NVS), and Corcept Therapeutics, Inc. (NASDAQ: CORT). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

The following slide deck was published by Corcept Therapeutics Incorporated in conjunction with their 2022 Q1 earnings call.

CORT earnings call for the period ending March 31, 2022.